Caris Life Sciences (CAI) Asset Utilization Ratio (2025 - 2026)

Caris Life Sciences (CAI) recorded quarterly Asset Utilization Ratio of 0.79 in Q1 2026, up 3.05% quarter-over-quarter from 0.77 in Q4 2025.

Caris Life Sciences (CAI) Asset Utilization Ratio (2025 - 2026) Analysis & Trends

Caris Life Sciences' Asset Utilization Ratio history runs 2 years deep, the most recent figure standing at 0.79 for Q1 2026.

In Q1 2026, Asset Utilization Ratio changed N/A year-over-year to 0.79; the TTM figure through Mar 2026 stood at 0.79 (changed N/A YoY), while the FY2025 annual figure was 1.11, changed N/A from the prior year.
Asset Utilization Ratio was 0.79 for Q1 2026 at Caris Life Sciences, up from 0.77 in the prior quarter.
In the past five years, Asset Utilization Ratio ranged from a high of 0.79 in Q1 2026 to a low of 0.67 in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Asset Util. (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	0.55
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	0.60
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	1,422.00
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	0.47
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	Caris Life Sciences	5.22 Bn	4.40 Bn	171.13 Mn	0.79

Download Data